Brand name - Olumiant
Generic name - Baricitinib
Manufacturer - Eli Lilly and Co.
Salt composition - Baricitinib
Disease indication - Rheumatoid arthritis
Storage - Store at 20-25°C (68-77°F)
Dosage form - oral
Strength - 2mg, 4mg
Packaging - bottle of 30 tablets
Gender - Unisex
Indication - used in the treatment of adult patients with moderately to severely active Rheumatoid Arthritis.
Olumiant (baricitinib) is used for the treatment of adult patients with active rheumatoid arthritis, who already have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies. Baricitinib blocks the activity of certain enzymes that are involved in activating inflammation in the body. Olumiant 2 mg tablet is light pink, debossed with “Lilly” on one side and “2” on the other. Olumiant 4 mg tablet is light pink, debossed with “Lilly” on one side and “4” on the other.
Baricitinib is a selective and reversible Janus kinase 1 (JAK1) and 2 (JAK2) inhibitor. Janus kinases belong to the tyrosine protein kinase family. They play a crucial role in the proinflammatory pathway signalling that is frequently over-activated in rheumatoid arthritis. By blocking the actions of JAK1/2, baricitinib works to disrupt the activation of downstream signalling molecules and proinflammatory mediators.
Baricitinib inhibition of IL-6 induced STAT3 phosphorylation
Baricitinib administration resulted in a dose-dependent inhibition of IL-6 induced STAT3 phosphorylation in whole blood from healthy subjects with maximal inhibition observed approximately 1 hour after dosing, which returned to near baseline by 24 hours. Similar levels of inhibition were seen using either IL-6 or TPO as the stimulus.
Mean serum IgG, IgM, and IgA values decreased by 12 weeks after starting treatment with Olumiant, and remained stable through at least 52 weeks. For most patients, changes in immunoglobulins occurred within the normal reference range.
In patients with rheumatoid arthritis, decreases in serum C-reactive protein (CRP) were observed as early as one week after starting treatment with Olumiant and were maintained throughout dosing.
At a dose 10 times the maximum recommended dose, baricitinib does not prolong the QT interval to any clinically relevant extent.
The active ingredient in Olumiant is Baricitinib. Other ingredients are croscarmellose sodium, magnesium stearate, mannitol, microcrystalline cellulose, iron oxide red, lecithin, macrogol 3350, polyvinyl alcohol, purified talc and titanium dioxide.
Usage of Olumiant (Baricitinib)
Olumiant (baricitinib) is used for the treatment of adult patients with active rheumatoid arthritis, who already have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.
Common side effects
Serious side effects
Shortness of breath
Difficulty in breathing
Skip the missed dose if it is already time for the next dose. Do not double the dose to catch up.
Seek emergency medical help in case of overdose.
Warning and precautions
Before consuming Olumiant (baricitinib), make sure to tell your healthcare provider if you:
Have or have had hepatitis B or C
Have blood clots in the veins of your legs or lungs.
Have kidney or liver problems
Have lung disease
Have a weak immune system
Have any stomach-area pain
Have been diagnosed with inflammation in the large intestine or ulcers in your stomach or intestines.
Have recently received a vaccine
Are planning to receive a vaccine
Are planning to become pregnant
Are breastfeeding or planning to breastfeed.
Are taking other medicines, including prescribed supplements.
Are under age 18 (because it is not known if Olumiant is safe and effective in children).
It is not known if Olumiant is safe and effective in children (below age 18).
It is recommended to not consume Olumiant (baricitinib) during breastfeeding.
Q1- What is Olumiant?
A- Olumiant (baricitinib) is used for the treatment of adult patients with active rheumatoid arthritis.
Q2- How should I take Olumiant?
A- Take Olumiant (baricitinib) exactly as your healthcare provider tells you.
Q3- What are the possible side effects of Olumiant?
A- There can be side effects such as fever, chills, muscle and joint pain, stomach pain, diarrhea, coughing up red mucus, rashes, sinus, difficulty in breathing and weight loss. If you experience these or any other side effects, please contact your healthcare provider.
Q4- In what strength is it available?
A- Baricitinib is available in the strength of 2mg and 4mg.
Q5- What happens if I miss a dose?
A- Skip the missed dose if it is already time for the next dose. Do not double the dose to catch up.
Q6- What should I avoid while consuming this medicine?
A- Do not receive a "live" vaccine while using Olumiant. Live vaccines include measles, mumps, rubella (MMR), polio, rotavirus, typhoid, yellow fever, varicella (chickenpox), and zoster (shingles).
Q7- What are self care tips?
A- Keep a note of all the side effects you experience and tell your healthcare provider.
Q8- Can I take this medicine during pregnancy?
A- Please consult your healthcare provider.
Q9- Can I drive after taking this medicine?
A- Baricitinib may cause tiredness. If you experience such side effects, avoid driving and operating heavy machines.
Q10- What are the storage conditions?
A- Store at 20-25°C (68-77°F).